To best protect the Juneau community against COVID-19, Bartlett Regional Hospital continues to offer monoclonal antibody therapy. Monoclonal antibody therapy is a safe and effective treatment that helps prevent severe illness and hospitalization from COVID-19 for individuals newly infected with the virus. You must receive this treatment within 10 days of when your symptoms started.
Criteria for therapy administration includes those at high risk for progressing to severe COVID-19, including people with pre-existing conditions, such as cardiovascular disease, or those with mild or moderate COVID-19 symptoms. Monoclonal antibodies can be given to vaccinated and unvaccinated individuals. Priority is given to individuals over 65 years of age. Treatment is available by appointment seven days a week.
If you think you or someone you know may meet criteria for monoclonal antibody therapy, contact your primary care provider for referral to BRH’s onsite monoclonal antibody clinic. Community members or visitors without a primary care provider can contact BRH at 796-8900 for more information. Eligibility for antibody therapy includes:
- Those over 65 years of age with cardiovascular disease, hypertension, chronic obstructive pulmonary disease, or chronic respiratory disease; OR
- Those with specific, rare, pre-existing conditions; OR
- Those with mild or moderate coronavirus disease; OR
- Those at high risk for progressing to severe COVID-19 and/or hospitalization
Antibody therapy is beneficial only in newly infected patients. Generally, a patient is not a candidate for therapy once hospitalized. Learn more here.
Monoclonal antibody therapy is not a substitution for getting vaccinated against COVID-19. Vaccination remains the single most effective strategy to fight infection from COVID-19.
For more information, contact BRH Chief Nursing Officer Kim McDowell at (907) 796-8310 or [email protected].